Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B

by Lau G.K.K., Piratvisuth T., Kang X.L., Marcellin P., Thongsawat S., Cooksley G., Gane E., Fried M.W., Wan C.C., Seung W.P., Wen Y.C., Berg T., Flisiak R., McCloud P., Pluck N.
Published 2014

Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection

by Colvin,R.A., Tanwandee,T., Piratvisuth,T., Thongsawat,S., Hui,A., Zhang,H., Ren,H., Chen,P., Chuang,W., Sobhonslidsuk,A., Li,R., Qi,Y., Præstgaard,J.T., Han,Y., Xu,J., Stein,D.S., Chien,R., Flisiak,R., Jabłkowski,M.S., Liaw,Y., Sung,J.J.Y.
Published 2015

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

by Pianko S., Zeuzem S., Chuang W.-L., Foster G.R., Sarin S.K., Flisiak R., Lee C.-M., Andreone P., Piratvisuth T., Shah S., Sood A., George J., Gould M., Komolmit P., Thongsawat S., Tanwandee T., Rasenack J., Li Y., Pang M., Yin Y., Feutren G., Jacobson I.M.
Published 2014

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

by Pianko S., Zeuzem S., Chuang WL., Foster GR., Sarin SK., Flisiak R., Lee CM., Andreone P., Piratvisuth T., Shah S., Sood A., George J., Gould M., Komolmit P., Thongsawat S., Tanwandee T., Rasenack J., Li Y., Pang M., Yin Y., Feutren G., Jacobson IM., for the B2202 Study Team.
Published 2014